Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the a…
Erfolgreiche Markteinführungen von Nubeqa™ und Kerendia™ / Asundexian potenzielle neue Behandlungsoption zur Thrombose-…
Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts Level 1 clinical…
• Im Sisslerfeld in der Gemeinde Eiken (Kanton Aargau) soll der dritte Bachem Standort in der Schweiz entstehen, nach Bu…
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that…
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs pro…
INTEGRA Biosciences arbeitet weiter an seinem nachhaltigen Ansatz zur Lieferung qualitativ hochwertiger Laborausrüstung…
Biesterfeld erweitert seine langjährige Partnerschaft mit dem US-amerikanischen Wirkstoffhersteller IFF Health & Bioscie…